3 Year Absolute Returns
32.24% ↑
NAV (₹) on 16 Nov 2026
180.45
1 Day NAV Change
-0.02%
Risk Level
Very High Risk
Rating
-
Nippon India Pharma Fund - Direct Plan is a Equity mutual fund categorized under Sector, offered by Nippon Life India Asset Management Ltd.. Launched on 01 Jan 2013, investors can start with a minimum ... Read more
AUM
₹ 9,087.25 Cr
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 78.01% |
| Hospitals & Medical Services | 20.80% |
| Chemicals - Speciality | 0.81% |
| Treps/Reverse Repo | 0.52% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.55% | ₹ 1,049.97 | Pharmaceuticals |
| Divi's Laboratories Limited | 6.73% | ₹ 611.99 | Pharmaceuticals |
| Cipla Limited | 6.21% | ₹ 564.67 | Pharmaceuticals |
| Lupin Limited | 6.16% | ₹ 559.86 | Pharmaceuticals |
| Dr. Reddy's Laboratories Limited | 6.13% | ₹ 556.82 | Pharmaceuticals |
| Apollo Hospitals Enterprise Limited | 5.10% | ₹ 463.62 | Hospitals & Medical Services |
| Mankind Pharma Limited | 4.40% | ₹ 399.74 | Pharmaceuticals |
| Sai Life Sciences Limited | 4.04% | ₹ 366.91 | Pharmaceuticals |
| Ajanta Pharma Limited | 3.53% | ₹ 320.68 | Pharmaceuticals |
| Max Healthcare Institute Limited | 3.31% | ₹ 300.84 | Hospitals & Medical Services |
| IPCA Laboratories Limited | 2.90% | ₹ 263.10 | Pharmaceuticals |
| GlaxoSmithKline Pharmaceuticals Limited | 2.83% | ₹ 256.78 | Pharmaceuticals |
| Gland Pharma Limited | 2.73% | ₹ 247.84 | Pharmaceuticals |
| Vijaya Diagnostic Centre Limited | 2.66% | ₹ 241.67 | Hospitals & Medical Services |
| Piramal Pharma Limited | 2.61% | ₹ 237.41 | Pharmaceuticals |
| MedPlus Health Services Limited | 2.26% | ₹ 205.59 | Pharmaceuticals |
| Fortis Healthcare Limited | 2.25% | ₹ 204.04 | Hospitals & Medical Services |
| Abbott India Limited | 2.22% | ₹ 201.35 | Pharmaceuticals |
| Dr. Lal Path Labs Limited | 2.10% | ₹ 190.75 | Hospitals & Medical Services |
| Thyrocare Technologies Limited | 1.93% | ₹ 175.13 | Hospitals & Medical Services |
| Alkem Laboratories Limited | 1.82% | ₹ 165.51 | Pharmaceuticals |
| Narayana Hrudayalaya Limited | 1.56% | ₹ 141.73 | Hospitals & Medical Services |
| Syngene International Limited | 1.55% | ₹ 141.01 | Pharmaceuticals |
| Aurobindo Pharma Limited | 1.42% | ₹ 128.93 | Pharmaceuticals |
| Suraksha Diagnostic Limited | 1.36% | ₹ 123.26 | Hospitals & Medical Services |
| Emcure Pharmaceuticals Limited | 1.32% | ₹ 119.97 | Pharmaceuticals |
| Anthem Biosciences Limited | 1.30% | ₹ 117.69 | Pharmaceuticals |
| Pfizer Limited | 1.29% | ₹ 117.36 | Pharmaceuticals |
| Akums Drugs and Pharmaceuticals Limited | 1.09% | ₹ 98.90 | Pharmaceuticals |
| Sanofi India Limited | 1.06% | ₹ 96.21 | Pharmaceuticals |
| Biocon Limited | 0.97% | ₹ 88.09 | Pharmaceuticals |
| Natco Pharma Limited | 0.90% | ₹ 81.37 | Pharmaceuticals |
| Sanofi Consumer Healthcare India Limited | 0.81% | ₹ 73.55 | Chemicals - Speciality |
| Molbio Diagnostics Limited | 0.53% | ₹ 48.45 | Hospitals & Medical Services |
| Triparty Repo | 0.52% | ₹ 47.35 | Others |
| AstraZeneca Pharma India Limited | 0.46% | ₹ 42.15 | Pharmaceuticals |
| Indoco Remedies Limited | 0.38% | ₹ 34.40 | Pharmaceuticals |
| Concord Biotech Limited | 0.15% | ₹ 13.92 | Pharmaceuticals |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | 16.33% | 5.37% | 1.07% | 9.76% |
| Category returns | 7.34% | 5.08% | 9.77% | 22.47% |
The primary investment objective of the scheme is to seek to generate continuous returns by investing in equity and equity related or fixed-income securities of Pharma and other associated companies.
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Pharma and Healthcare Fund - Direct Plan
Sector
Direct
|
₹23.46 | 30.32% | 124.36% | 0.00% | ₹3,666 | 1.03% |
Very High
|
What is the current NAV of Nippon India Pharma Fund - Direct Plan IDCW?
What is the fund size (AUM) of Nippon India Pharma Fund - Direct Plan IDCW?
What are the historical returns of Nippon India Pharma Fund - Direct Plan IDCW?
What is the risk level of Nippon India Pharma Fund - Direct Plan IDCW?
What is the minimum investment amount for Nippon India Pharma Fund - Direct Plan IDCW?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article